STOCKS TELEGRAPH

Tag: ThermoGenesis Holdings Inc

  • ThermoGenesis Holdings Inc. (THMO) stock Recovers in the After Hours

    On February 11, 2022, ThermoGenesis Holdings Inc. (THMO) stock made a comeback in the after-hours to gain 7.19%. There has been no recent official announcement or SEC filing from the company.

    The stock remained in the red with a loss of 2.97% in the regular trading session. THMO closed the session at $0.8303 with a below-average volume of 211.82K shares. The stock rebounded in the after-hours and gained $0.06 or 7.19%. Hence, on February 11, THMO stock was trading at a value of $0.8900 per share in the after-hours session.

    The cell and gene therapy automated cell processing technologies developer, ThermoGenesis Holdings Inc. has a market capitalization of $9.89 million. Currently, the company has 11.91 million shares outstanding in the market.

    Why THMO Rebounded?

    There has been no recent announcement or SEC filing from the company to explain the stock’s movement. On Wednesday and Thursday, THMO stock remained bullish to increase from $0.8300 to $0.8600. Following the gain, the stock entered a downtrend on Friday, during the regular session. It seems the stock suffered a downfall due to profit booking from the gains. Subsequently, the stock once again resumed its bullish momentum in the after-hours on Friday.

    An overview of the stock’s movement shows a picture in red with losses. THMO has lost 17.79% year to date while it subtracted a huge value of 78.49% last year.

    Annual Meeting of Stockholder

    The company’s 2021 Annual Meeting of Stockholders was initially set to take place on December 16, 2021. Due to the lack of the required quorum, the meeting was adjourned without conducting business.

    The company then reconvened the meeting on Thursday, January 13, 2022, at its corporate headquarters in Rancho Cordova, CA.

    Moreover, only the stockholders of the previous record date, October 26, 2021, were allowed to vote in the meeting.

    THMO’s Recent Participation

    Recently, the company participated in the H.C. Wainwright BioConnect Virtual Conference. The conference took place from January 10 to January 13, 2022. THMO’s Chief Financial Officer, Jeff Cauble presented an overview of the company at the conference.

    Financial Analysis

    In the third quarter of 2021, the company generated net revenues of $3.2 million against $2.4 million in the year-ago period. This marks an increase of 34% YOY.

    Furthermore, THMO incurred a comprehensive net loss of $1.8 million in Q3 2021, against $2.5 million in the prior-year period. Therefore, the net loss per basic and diluted share was $0.15 and $0.37 in the third quarter of 2021 and 2020 respectively.

  • High Flying Plasma Pharmaceuticals as FDA Approves Plasma-based COVID-19 Treatment

    High Flying Plasma Pharmaceuticals as FDA Approves Plasma-based COVID-19 Treatment

    The markets are up this morning driven by news that the U.S had approved a COVID-19 treatment. Yesterday, the U. S FDA issued an emergency use authorization for the use of blood plasma from people who had recovered from COVID-19 as a treatment.

    In a statement, the FDA said that on the basis of available scientific evidence, the blood plasma of people who had recovered from COVID-19 had benefits that outweighed any potential risks. The statement further stated that the Emergency Use Authorization gave the green light for the distribution of the product in the U.S for use by healthcare providers to treat people hospitalized with COVID-19.

    Commenting on the development, President Trump has stated that the treatment had so far cut mortality rates by 35%, quoting a study by the Mayo Clinic. Over the weekend, it was also reported that the President was considering fast-tracking a vaccine that was being developed by Oxford University in the U.K.

    All these news have led to a surge in optimism across the financial markets, and major U.S indices are strong pre-market. In this environment of high optimism, plasma-related biopharma companies are rallying. Some of the biggest gainers this morning are as below:

    ADMA Biologics Inc [NASDAQ: ADMA]

    ADMA Biologics is flying high this morning after the FDA approved the use of recovered COVID-19 patients’ plasma as a treatment.

    At the time of writing, the stock was up by 70% and gaining. The company is specialized in making plasma biologics for the treatment of a wide array of immune deficiencies and infectious diseases. With the use of plasma approved, investors are optimistic that with its infrastructure in plasma-based treatments, this company stands to benefit significantly in the foreseeable future.

    ThermoGenesis Holdings Inc [NASDAQ: THMO]

    ThermoGenesis Holdings Inc is another plasma-treatment biotech company that is rallying this morning.  The company has the infrastructure for it, and investors are optimistic that it stands to benefit from the approved treatment.

    The company operates in two segments and one of them is involved in automated cell separation of progenitor and stem cells taken from umbilical cords blood. It is also involved in the preservation of such blood for clinical applications.

    Liminal Biosciences Inc [NASDAQ: LMNL]

    This is another top performer this morning and is up by over 60% in pre-market trading. The company operates in two segments and one of them is called Plasma Derived Therapeutics. This segment of the company has a plasma protein purification system that is used in the extraction of protein therapeutics from plasma.